Kamada Ltd.
A biopharmaceutical company specializing in plasma-derived protein therapeutics.
KMDA | TA
Overview
Corporate Details
- ISIN(s):
- IL0010941198
- LEI:
- Country:
- Israel
- Address:
- 2 Holzman St, Science Park, 7670402 Rehovot
- Website:
- https://www.kamada.com
- Sector:
- Manufacturing
Description
Kamada Ltd. is a vertically integrated global biopharmaceutical company specializing in plasma-derived protein therapeutics. The company develops, manufactures, and commercializes a portfolio of products for rare and serious conditions, with a focus on therapeutic areas such as Alpha-1 Antitrypsin Deficiency (AATD) and Cytomegalovirus (CMV) prevention in transplant patients. Kamada utilizes a proprietary platform technology for advanced protein extraction and purification from human plasma. In addition to its marketed products, the company maintains a development pipeline of new therapies, including an inhaled treatment for AATD.
Unlock This Filing & Millions More
You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.
Filings
| Date | Filing | Language | Size | Actions | |
|---|---|---|---|---|---|
| 2020-11-12 15:05 |
6K: Financial Statements as of September 30, 2020 (Unaudited)
|
English | 36.1 KB | ||
| 2020-11-11 15:02 |
Third Quarter Ended September 30, 2020
|
English | 269.8 KB | ||
| 2020-11-11 15:02 |
Third Quarter Ended September 30, 2020
|
English | 36.0 KB | ||
| 2020-11-04 15:10 |
Kamada to Announce Third Quarter Ended September 30, 2020 Financial Results and…
|
English | 139.1 KB | ||
| 2020-11-04 15:10 |
Kamada to Announce Third Quarter Ended September 30, 2020 Financial Results and…
|
English | 36.0 KB | ||
| 2020-10-30 00:39 |
Proxy Statement for the 2020 Annual General Meeting of Shareholders to be held …
|
English | 360.4 KB | ||
| 2020-10-30 00:39 |
Proxy Statement for the 2020 Annual General Meeting of Shareholders to be held …
|
English | 36.0 KB | ||
| 2020-10-19 16:06 |
Announces Supply Agreement with Israeli Ministry of Health for its Investigatio…
|
English | 180.5 KB | ||
| 2020-10-19 16:06 |
Announces Supply Agreement with Israeli Ministry of Health for its Investigatio…
|
English | 36.1 KB | ||
| 2020-10-07 15:40 |
Kamada Provides Update on 2021 GLASSIA® Supply to Takeda
|
English | 177.3 KB | ||
| 2020-10-07 15:40 |
Kamada Provides Update on 2021 GLASSIA® Supply to Takeda
|
English | 35.9 KB | ||
| 2020-09-08 16:00 |
Results from its Phase 1/2 Clinical Trial in Israel of its Plasma-Derived Hyper…
|
English | 174.9 KB | ||
| 2020-09-08 16:00 |
Results from its Phase 1/2 Clinical Trial in Israel of its Plasma-Derived Hyper…
|
English | 36.2 KB | ||
| 2020-08-19 16:03 |
Announce Results of KEDRAB in Children
|
English | 202.1 KB | ||
| 2020-08-19 16:03 |
Announce Results of KEDRAB in Children
|
English | 36.1 KB |
Automate Your Workflow. Get a real-time feed of all Kamada Ltd. filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
Unlock Full Financials for Kamada Ltd.
This data is available as part of our premium data solutions. Contact our team for access.
Need More History? Access decades of standardized financials for Kamada Ltd. via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| No insider transactions recorded for this company. | |||||
Peer Companies
